Table 2.
Cancer screening rates for five major cancers in Korea, 2004–2018
| Survey year | Trend 1 | Trend 2 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|||||||||||||||
| 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | APC (year) | APC (year) | |
| Lifetime screening rate (%)a) | |||||||||||||||||
|
| |||||||||||||||||
| Stomach | 52.0 | 48.5 | 53.5 | 55.3 | 65.0 | 65.1 | 76.7 | 76.2 | 77.9 | 80.0 | 83.4 | 83.0 | 85.2 | 84.0 | 85.5 | 4.61* (’04–’11) | 1.03* (’11–’18) |
|
| |||||||||||||||||
| Liver | 31.8 | 47.7 | 58.3 | 57.6 | 64.8 | 81.3 | 54.2 | 54.3 | 69.9 | 49.3 | 48.1 | 61.2 | 51.9 | 74.9 | 55.7 | 13.76 (’04–’06) | −0.10 (’06–’18) |
|
| |||||||||||||||||
| Colorectal | 25.3 | 27.9 | 34.0 | 40.7 | 50.4 | 48.1 | 57.1 | 56.1 | 65.8 | 70.3 | 75.6 | 77.1 | 76.7 | 75.7 | 77.0 | 5.11* (’04–’14) | 0.29 (’14–’18) |
|
| |||||||||||||||||
| Breast | 55.9 | 57.4 | 60.2 | 66.4 | 72.7 | 78.1 | 79.5 | 79.0 | 82.9 | 83.1 | 85.8 | 84.6 | 81.3 | 86.2 | 83.1 | 4.51* (’04–’10) | 0.54 (’10–’18) |
|
| |||||||||||||||||
| Cervical | 76.8 | 74.0 | 68.0 | 73.6 | 74.4 | 76.1 | 75.0 | 74.8 | 77.1 | 76.2 | 74.6 | 76.2 | 72.7 | 76.5 | 66.6 | 0.29 (’04–’16) | −4.02 (’16–’18) |
|
| |||||||||||||||||
| Screening rates with recommendations (%)b) | |||||||||||||||||
|
| |||||||||||||||||
| Stomachc) | 39.2 | 39.4 | 43.3 | 45.6 | 53.5 | 56.9 | 65.1 | 64.6 | 70.9 | 73.6 | 76.7 | 74.8 | 73.0 | 72.2 | 72.8 | 4.38* (’04–’13) | −0.47 (’13–’18) |
|
| |||||||||||||||||
| Upper endoscopy | 32.4 | 32.9 | 33.5 | 37.8 | 44.8 | 49.3 | 58.9 | 58.1 | 63.3 | 64.4 | 67.4 | 64.7 | 64.8 | 64.3 | 64.7 | 4.69* (’04–’12) | 0.01 (’12–’18) |
|
| |||||||||||||||||
| UGI series | 13.0 | 13.1 | 15.2 | 20.4 | 21.1 | 19.5 | 24.9 | 25.3 | 26.4 | 24.9 | 21.9 | 24.6 | 24.5 | 28.5 | 24.9 | 2.10* (’04–’10) | 0.07 (’10–’18) |
|
| |||||||||||||||||
| Liverd) | 20.0 | 16.3 | 16.5 | 22.7 | 19.7 | 31.3 | 22.9 | 22.9 | 21.5 | 33.6 | 25.2 | 28.1 | 27.7 | 34.5 | 26.2 | 1.51* (’04–’13) | 0.07 (’13–’18) |
|
| |||||||||||||||||
| Colorectale) | 19.9 | 25.4 | 29.4 | 34.1 | 37.9 | 36.7 | 35.5 | 35.3 | 44.7 | 55.6 | 60.1 | 59.5 | 54.6 | 56.8 | 58.4 | 3.59* (’04–’14) | 0.68 (’14–’18) |
|
| |||||||||||||||||
| Colonoscopy | 14.4 | 12.4 | 16.8 | 19.5 | 19.1 | 23.4 | 23.3 | 23.6 | 30.1 | 35.2 | 37.3 | 38.5 | 40.0 | 40.6 | 45.4 | 2.02* (’04–’10) | 2.66* (’10–’18) |
|
| |||||||||||||||||
| DCBE | 2.8 | 4.1 | 5.3 | 8.7 | 7.0 | 6.1 | 6.1 | 6.0 | 3.8 | 7.0 | 4.7 | 4.2 | 6.9 | 8.2 | 7.9 | −0.07 (’04–’15) | 0.97 (’15–’18) |
|
| |||||||||||||||||
| FOBT | 3.8 | 7.2 | 13.6 | 20.2 | 20.9 | 19.0 | 25.9 | 25.0 | 29.6 | 27.6 | 29.1 | 30.6 | 25.9 | 33.5 | 20.0 | 2.24* (’04–’15) | −4.28* (’15–’18) |
|
| |||||||||||||||||
| Breastf) | 33.2 | 38.4 | 40.6 | 45.8 | 49.3 | 55.2 | 61.6 | 60.4 | 70.9 | 59.7 | 66.0 | 61.2 | 62.9 | 63.6 | 63.1 | 4.05* (’04–’12) | −0.75 (’12–’18) |
|
| |||||||||||||||||
| Cervicalg) | 58.3 | 57.0 | 54.9 | 57.0 | 59.9 | 63.9 | 62.9 | 62.4 | 67.9 | 67.0 | 66.1 | 65.6 | 62.1 | 66.8 | 55.6 | 1.21* (’04–’14) | −2.07 (’14–’18) |
|
| |||||||||||||||||
| 56.6h) | 56.6h) | 56.3h) | 60.7h) | 49.3h) | −2.45h) (’14–’18) | ||||||||||||
APC, annual percentage change; DCBE, double-contrast barium enema; FOBT, fecal occult blood test; UGI, upper gastrointestinal.
Significantly different from zero (p < 0.05).
Lifetime screening rate was defined as the proportion of respondents who ever underwent the screening test(s),
Screening rate with recommendation was defined as the proportion of respondents who fulfilled the screening recommendation criteria among the respondents in the targeted age group for the relevant cancer,
Respondents who had last undergone upper endoscopy or UGI series screening within 2 years, among men and women aged ≥ 40 years,
Respondents who had last undergone screening with abdominal ultrasonography and serum α-fetoprotein within 6 months, among men and women aged ≥ 40 years who were at high risk for liver cancer (i.e., those with hepatitis B virus surface antigen (+), hepatitis C virus antibody (+), or liver cirrhosis),
Respondents who had last undergone screening with colonoscopy, DCBE, or FOBT within 5, 5, and 1 year, respectively, before 2009, and within 10, 5, and 1 year, respectively, after 2009, among men and women aged ≥ 50 years,
Respondents who had last undergone screening with mammography within 2 years, among women aged ≥ 40 years,
Respondents who had last undergone screening with conventional cytology within 2 years,
among women aged ≥ 30 years, ≥ 20 years.